Results 191 to 200 of about 32,728,881 (336)

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Collusion under Monitoring of Sales [PDF]

Collusion under imperfect monitoring is explored when firms?prices are private information and their quantities are public information; an information structure consistent with several recent price-fixing cartels such as those in lysine and vitamins. For
Jr Andrzej Skrzypacz, Joseph E Harrington   +1 more
core  

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

British Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić, Marta Kučan Štiglić, Ana Jelaković, Bojan Jelaković, Dinko Vitezić   +4 more
wiley   +1 more source

Are Short-sellers Different? [PDF]

While theoretical models strongly suggest that short-sales are mainly driven by private information, recent empirical evidence of has been rather mixed.
Bardong, Florian, Yadav, Pradeep K., Bartram, Söhnke M.   +2 more
core  

Trends in publicly subsidized and private access to GLP‐1 medicines indicated for type 2 diabetes in Australia, 2020–2025

British Journal of Clinical Pharmacology, EarlyView.
Aims GLP‐1 medicines provide substantial cardio‐renal benefits for type 2 diabetes (T2D) and are increasingly used for weight loss. Most high‐income countries subsidize access for T2D with restrictions; use outside of these restrictions occurs through private prescriptions. Despite strong consumer demand, the extent of private access to GLP‐1 medicines
Michael O. Falster, Juliana de Oliveira Costa, Tamara Y. Milder, Joanne Carson, Cade Shadbolt, Brendon L. Neuen, Clare Arnott, Andrew Wilson, Min Jun, Nicole Pratt, Sallie‐Anne Pearson   +10 more
wiley   +1 more source

When do book-tax differences matter for earnings persistence? The role of sales decline. [PDF]

PLoS One
Tuan DA, Dung NNK.
europepmc   +1 more source

Twenty years of inhaler therapy: A nationwide drug utilization study

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to map nationwide trends and prescribing patterns in inhaler use from 2004 to 2023. In light of evolving clinical guidelines and attention to the environmental impact of inhalers within recent years, we also examined variation in prescribing behaviour and patient‐level treatment choices. Methods Using nationwide health registries,
Katrine Bitsch Johansen, Lars Christian Lund, Zandra Nymand Ennis, Andrew Scourfield, Anders Løkke, Sidsel Arnspang Pedersen   +5 more
wiley   +1 more source

Large nutritional and environmental improvements can be achieved across the product portfolios of major UK food and beverage manufacturers. [PDF]

Nat Food
Hammond E, Bandy L, Milner-Gulland EJ, Pechey R, Rayner M, Scarborough P, Jain S, Clark M.   +7 more
europepmc   +1 more source

Information Sales and Insider Trading with Long-lived Information [PDF]

Fundamental information resembles in many respects a durable good. Hence, the effects of its incorporation into stock prices depend on who is the agent controlling its flow.
Giovanni Cespa
core  

Defining a comprehensive set of value assessment criteria for funders of drug repurposing initiatives

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aims to develop a structured list of value assessment criteria for drug repurposing (DR) projects designed to support consistent, evidence‐informed decision‐making by funders. The assessment criteria were developed within the REMEDi4ALL project, a multi‐stakeholder Horizon Europe funded initiative to advance DR and were validated ...
Dalma Hosszú, Kristóf Gyöngyösi, András Perényi, Helene G. van der Meer, Dunja Huijbers, Pan Pantziarka, András Inotai, Donald C. Lo, Rick Thompson, Zoltán Kaló, Marcell Csanádi   +10 more
wiley   +1 more source